SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Raab G, Klagsbrun M. Heparin binding EGF growth factor. Biochim Biophys Acta 1997; 1333: F17999.
  • 2
    Iwamoto R, Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev 2000; 11: 33544.
  • 3
    Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A 1994; 91: 28904.
  • 4
    Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004; 64: 528390.
  • 5
    Thompson SA, Higashiyama S, Wood K, Pollitt NS, Damm D, McEnroe G, et al. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. J Biol Chem 1994; 269: 25419.
  • 6
    Leach RE, Kilburn B, Wang J, Liu Z, Romero R, Armant DR. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Dev Biol 2004; 266: 22337.
  • 7
    Leach RE, Khalifa R, Ramirez ND, Das SK, Wang J, Dey SK, et al. Multiple roles for heparin-binding epidermal growth factor-like growth factor are suggested by its cell-specific expression during the human endometrial cycle and early placentation. J Clin Endocrinol Metab 1999; 84: 335563.
  • 8
    Leach RE, Romero R, Kim YM, Chaiworapongsa T, Kilburn B, Das SK, et al. Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Lancet 2002; 360: 12159.
  • 9
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295306.
  • 10
    Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 23650.
  • 11
    Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, et al. Anti-β2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007; 5: 24218.
  • 12
    Tripodi A, Mancuso ME, Chantarangkul V, Clerici M, Bader R, Meroni PL, et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 2005; 51: 18835.
  • 13
    Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, Cattaneo R, et al. The anti-β2-glycoprotein I activity in human antiphospholipid syndrome sera is due to monoreactive low affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species evolution. J Immunol 1996; 157: 57328.
  • 14
    Di Simone N, Raschi E, Testoni C, Castellani R, D'Asta M, Shi T, et al. Pathogenic role of anti-β2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of β2-glycoprotein I binding to trophoblast cells and functional effects of anti-β2-glycoprotein I antibodies in vitro. Ann Rheum Dis 2005; 64: 4627.
  • 15
    Zhu M, Olee T, Le DT, Roubey RA, Hahn H, Woods VL, et al. Characterization of IgG monoclonal anti-cardiolipin/anti-β2GPI antibodies from two patients with the anti-phospholipid syndrome reveals three species of antibodies. Br J Haematol 1999; 105: 1029.
  • 16
    Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss JF. Purification, characterization and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 1986; 118: 156782.
  • 17
    Di Simone N, Meroni PL, Del Papa N, Raschi E, Caliandro D, De Carolis S, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered β2-glycoprotein I. Arthritis Rheum 2000; 43: 14051.
  • 18
    Di Simone N, Maggiano N, Caliandro D, Riccardi P, Evangelista E, Carducci B, et al. Homocysteine induces trophoblast cell death with apoptotic features. Biol Reprod 2003; 69: 112934.
  • 19
    Di Simone N, Di Nicuolo F, Sanguinetti M, Ferrazzani S, D'Alessio MC, Castellani R, et al. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta 2007; 28: 298304.
  • 20
    Armant DR, Kilburn BA, Petkova A, Edwin SS, Duniec-Dmuchowski ZM, Edwards HJ, et al. Human trophoblast survival at low oxygen concentrations requires metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor. Development 2005; 133: 7519.
  • 21
    Chamley LM, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to β2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352: 10378.
  • 22
    Ornoy A, Yacobi S, Matalon ST, Blank M, Blumenfeld Z, Miller RK, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 2003; 12: 5738.
  • 23
    Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H, et al. Expression and activation of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003; 24: 5364.
  • 24
    Librach CL, Werb Z, Fitzgerald ML, Chiu K, Corwin NM, Esteves RA, et al. 92-kDa Type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol 1991; 113: 43749.
  • 25
    Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar E, Yagel S. Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am J Obstet Gynecol 1994; 171: 8328.
  • 26
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 16174.
  • 27
    Sawicki G, Radomski MW, Winkler-Lowen B, Krzymien A, Guilbert LJ. Polarized release of matrix metalloproteinase-2 and -9 from cultured human placental syncytiotrophoblasts. Biol Reprod 2000; 63: 13905.
  • 28
    Erkan D, Patel S, Nuzzo M, Gerosa M, Meroni PL, Tincani A, et al. Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. Rheumatology (Oxford) 2008; 47 Suppl 3: iii237.
  • 29
    Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 2007; 3: 1407.
  • 30
    Guerin J, Sheng Y, Reddel S, Iverson GM, Chapman MG, Krilis SA. Heparin inhibits the binding of β2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein: elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 2002; 277: 26449.